Beyond neurological disease: New targets for edaravone (Review)

  • Authors:
    • Kiyoshi Kikuchi
    • Hisaaki Uchikado
    • Naohisa Miyagi
    • Yoko Morimoto
    • Takashi Ito
    • Salunya Tancharoen
    • Naoki Miura
    • Kei Miyata
    • Rokudai Sakamoto
    • Chiemi Kikuchi
    • Narumi Iida
    • Naoto Shiomi
    • Terukazu Kuramoto
    • Ko-Ichi Kawahara
  • View Affiliations

  • Published online on: September 15, 2011     https://doi.org/10.3892/ijmm.2011.795
  • Pages: 899-906
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Free radicals play major roles in the pathogenesis of tissue damage in many diseases and clinical conditions, and the removal of free radicals may offer a treatment option. Several modulators of free radical scavenger pathways have been developed and some have progressed to clinical trials. One such agent, edaravone, was approved in 2001 in Japan for the treatment of cerebral infarction. It has since been shown that edaravone can diffuse into many organs and, in addition to its effects on hydroxyl radical removal, edaravone modulates inflammatory processes, matrix metalloproteinase levels, nitric oxide production, apoptotic cell death, and necrotic cell death. Edaravone also exerts protective effects in a number of animal models of disease and tissue damage, including models of myocardial, lung, intestinal, liver, pancreatic and renal injury. Together with the proven safety of edaravone following 9 years of use as a modulator of free radical scavenging pathways in neurological disease, these additional effects of edaravone suggest that it may offer a novel treatment for several non-neurological diseases and clinical conditions in humans.

Related Articles

Journal Cover

December 2011
Volume 28 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kikuchi K, Uchikado H, Miyagi N, Morimoto Y, Ito T, Tancharoen S, Miura N, Miyata K, Sakamoto R, Kikuchi C, Kikuchi C, et al: Beyond neurological disease: New targets for edaravone (Review) . Int J Mol Med 28: 899-906, 2011.
APA
Kikuchi, K., Uchikado, H., Miyagi, N., Morimoto, Y., Ito, T., Tancharoen, S. ... Kawahara, K. (2011). Beyond neurological disease: New targets for edaravone (Review) . International Journal of Molecular Medicine, 28, 899-906. https://doi.org/10.3892/ijmm.2011.795
MLA
Kikuchi, K., Uchikado, H., Miyagi, N., Morimoto, Y., Ito, T., Tancharoen, S., Miura, N., Miyata, K., Sakamoto, R., Kikuchi, C., Iida, N., Shiomi, N., Kuramoto, T., Kawahara, K."Beyond neurological disease: New targets for edaravone (Review) ". International Journal of Molecular Medicine 28.6 (2011): 899-906.
Chicago
Kikuchi, K., Uchikado, H., Miyagi, N., Morimoto, Y., Ito, T., Tancharoen, S., Miura, N., Miyata, K., Sakamoto, R., Kikuchi, C., Iida, N., Shiomi, N., Kuramoto, T., Kawahara, K."Beyond neurological disease: New targets for edaravone (Review) ". International Journal of Molecular Medicine 28, no. 6 (2011): 899-906. https://doi.org/10.3892/ijmm.2011.795